How the health priorities affect PHARMAC's work
PHARMAC uses the Government's health priorities when considering funding a medicine or medical device.
Priority 1: Child wellbeing
PHARMAC's decisions will help improve child wellbeing and support children to have a healthy start in life.
Priority 2: Mental wellbeing
PHARMAC's decisions will help improve mental wellbeing. For PHARMAC, this includes treatment for alcohol and drug addiction.
Priority 3: Prevention
PHARMAC's decisions will improve wellbeing by preventing health conditions.
In his 2020/21 Letter of Expectations to PHARMAC, the Minister of Health asked PHARMAC to “consider how the prioritisation of medications to support improving wellbeing through prevention should be addressed”.
This includes issues such as:
- smoking cessation
- immunising against infectious diseases
- antimicrobial stewardship
- sexual health.
Priority 4: Health equity
PHARMAC's decisions will support better population outcomes, supported by a strong and equitable public health and disability system.
We are focused on achieving equity in health outcomes and enhancing equitable access to medicines.
This includes a specific focus on achieving pae ora (healthy futures) for Māori as Te Tiriti partners.
PHARMAC's equity priorities
- Priority populations: Māori, Pacific people, low socio-economic status, refugees, rural populations.
- Priority health conditions: cardiovascular disease, diabetes, asthma, COPD, gout.
PHARMAC's Hauora Arotahi (Māori health areas of focus) are:
- mental health
- heart health
- respiratory health
- cancer (lung and breast).
Priority 5: Primary health care
PHARMAC's decisions will support better population health and outcomes supported by primary care.
We are focused on strengthening primary care through making medicines available and accessible in primary care settings.
These conditions are government priorities. In addition to these priorities, PHARMAC takes into account a range of factors when making decisions.
This covers conditions that meet PHARMAC’s definition of a rare disease (1:50,000 population).
We consider that this includes all cancer conditions. However, note that some specific cancers (lung and breast) have a particular focus for PHARMAC under the Hauora Arotahi Māori health areas of focus.
We consider that long-term conditions include:
- cardiovascular disease
- chronic respiratory disease
- neurological diseases (such as dementia).
We consider that this covers both treatments for and immunisation to prevent infectious diseases.
We will also continue to promote the responsible use of antimicrobials (including antibiotics) – antimicrobial stewardship.
Read more about all the things PHARMAC considers when deciding to fund a medicine or medical device.